Michael Krainock

Michael Krainock

Company: Natera

Job title: Oncology Medical Director

Seminars:

Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC 2:30 pm

Latest clinical data from 2022 publications and presentations Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readoutRead more

day: Day One

Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors 12:30 pm

Understanding the different current comparators and benchmarks Exploring the differences in PD-1 naïve and PD-1 progressors Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar Discussing whether with late-line in-effectivity, how you know it won’t work in early line? Considering the health authorities’ standards on the matterRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.